We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Broad Approach Required for Histoplasmosis Diagnosis

By LabMedica International staff writers
Posted on 06 Sep 2011
An immunoassay has been used to improve the diagnosis of histoplasmosis, which is often diagnosed by a combining antigen and antibody testing, as well as culture and pathology. More...


The sensitivity of the MVista Histoplasma antigen enzyme immunoassay (EIA) has been evaluated in disseminated histoplasmosis in patients with Acquired Immunodeficiency Syndrome (AIDS) and in the “epidemic” form of acute pneumonia.

Scientist at Indiana University (Indianapolis, IN, USA) collected serum and urine samples from 218 patients with histoplasmosis; 158 with disseminated disease and 60 with pulmonary infection, and 229 controls. The patients evaluated came from eight medical centers during the period from November 2004 through December 2007, and they were tested for Histoplasma and/or Blastomyces antigen at a commercial laboratory. The MVista Histoplasma antigen EIA was modified to permit quantification below the level of 0.6 ng/mL by incorporating 0.2 ng/mL and 0.4 ng/mL calibrators and removing those of ≥19 ng/mL. Serum specimens were treated with 4% EDTA at 104 °C before testing.

In the group with disseminated histoplasmosis, the rate of antigenuria, the presence of the specific antigen in the urine, was 91.8%. Sensitivity for the presence of the specific antigen in the serum, antigenemia, was similar. Culture findings were positive in 74.2% of cases, and similar rates were seen with pathology (76.3%) and antibody testing (75.0%). The sensitivity of the test in pulmonary cases varied, as antigenuria was positive in 83.3% of acute cases, in 87.5% of chronic cases, but in only 30.4% of subacute cases. Conversely, antibody results were positive in 66.7%, 95.1%, and 83.3% of those three categories, respectively. The control group included 30 subjects with blastomycosis, and the histoplasmosis tests were 90% cross-reactive in this group. However, the histoplasmosis antigen-enzyme immunoassay was 99% specific when tested in healthy subjects and those with nonfungal infections.

MVista Histoplasma antigen quantative sandwich EIA is a product of MiraVista Diagnostics (Indianapolis, IN, USA) where the laboratory analysis was carried out. Chadi A. Hage, MD, the senior author of the study, and his colleagues concluded that their study supports a broad approach, using antigen testing of urine and serum samples, antibody testing, culture, and pathology for diagnosis of disseminated or pulmonary histoplasmosis. The study was published online on August 2, 2011, in the journal Clinical Infectious Diseases.

Related Links:

Indiana University
MiraVista Diagnostics




New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Fusun Can (at left) is developing a test for detecting both resistance and virulence in Klebsiella pneumoniae (Photo courtesy of Koç University)

Rapid Diagnostic Breakthrough Simultaneously Detects Resistance and Virulence in Klebsiella Pneumoniae

Antibiotic resistance is a steadily escalating threat to global healthcare, making common infections harder to treat and increasing the risk of severe complications. One of the most concerning pathogens... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.